BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33876771)

  • 1. Integrated mutational landscape analysis of uterine leiomyosarcomas.
    Choi J; Manzano A; Dong W; Bellone S; Bonazzoli E; Zammataro L; Yao X; Deshpande A; Zaidi S; Guglielmi A; Gnutti B; Nagarkatti N; Tymon-Rosario JR; Harold J; Mauricio D; Zeybek B; Menderes G; Altwerger G; Jeong K; Zhao S; Buza N; Hui P; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Ardighieri L; Bilguvar K; Quick CM; Silasi DA; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Imielinski M; Schwartz PE; Alexandrov LB; Lifton RP; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2021 Apr; 118(15):. PubMed ID: 33876771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma.
    Harold J; Bellone S; Manavella DD; Mutlu L; McNamara B; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MS; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2023 Jan; 168():157-165. PubMed ID: 36442427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.
    Bellone S; Jeong K; Halle MK; Krakstad C; McNamara B; Greenman M; Mutlu L; Demirkiran C; Hartwich TMP; Yang-Hartwich Y; Zipponi M; Buza N; Hui P; Raspagliesi F; Lopez S; Paolini B; Milione M; Perrone E; Scambia G; Altwerger G; Ravaggi A; Bignotti E; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Quick CM; Angioli R; Terranova C; Zaidi S; Nandi S; Alexandrov LB; Siegel ER; Choi J; Schlessinger J; Santin AD
    Proc Natl Acad Sci U S A; 2024 Apr; 121(17):e2321898121. PubMed ID: 38625939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor.
    McNamara B; Harold J; Manavella D; Bellone S; Mutlu L; Hartwich TMP; Zipponi M; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Yang K; Choi J; Dong W; Buza N; Hui P; Altwerger G; Huang GS; Andikyan V; Clark M; Ratner E; Azodi M; Schwartz PE; Burton EA; Inagaki H; Albers A; Zhang C; Bollag G; Schlessinger J; Santin AD
    Gynecol Oncol; 2023 May; 172():65-71. PubMed ID: 36958197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas.
    Moukarzel LA; Ferrando L; Da Cruz Paula A; Brown DN; Geyer FC; Pareja F; Piscuoglio S; Papanastasiou AD; Fusco N; Marchiò C; Abu-Rustum NR; Murali R; Brogi E; Wen HY; Norton L; Soslow RA; Vincent-Salomon A; Reis-Filho JS; Weigelt B
    Mol Oncol; 2021 Apr; 15(4):1024-1039. PubMed ID: 33021035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250).
    Ingham M; Allred JB; Chen L; Das B; Kochupurakkal B; Gano K; George S; Attia S; Burgess MA; Seetharam M; Boikos SA; Bui N; Chen JL; Close JL; Cote GM; Thaker PH; Ivy SP; Bose S; D'Andrea A; Marino-Enriquez A; Shapiro GI; Schwartz GK
    J Clin Oncol; 2023 Sep; 41(25):4154-4163. PubMed ID: 37467452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma.
    Dermawan JK; Chiang S; Singer S; Jadeja B; Hensley ML; Tap WD; Movva S; Maki RG; Antonescu CR
    Clin Cancer Res; 2024 May; 30(10):2260-2271. PubMed ID: 38488807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
    Ding YC; Song H; Adamson AW; Schmolze D; Hu D; Huntsman S; Steele L; Patrick CS; Tao S; Hernandez N; Adams CD; Fejerman L; Gardner K; Nápoles AM; Pérez-Stable EJ; Weitzel JN; Bengtsson H; Huang FW; Neuhausen SL; Ziv E
    Cancer Res; 2023 Aug; 83(15):2600-2613. PubMed ID: 37145128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMP14 expression and collagen remodelling support uterine leiomyosarcoma aggressiveness.
    Gonzalez-Molina J; Hahn P; Falcão RM; Gultekin O; Kokaraki G; Zanfagnin V; Braz Petta T; Lehti K; Carlson JW
    Mol Oncol; 2024 Apr; 18(4):850-865. PubMed ID: 37078535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of miR‑10b‑5p facilitates the proliferation of uterine leiomyosarcoma cells: A microRNA sequencing‑based approach.
    Yoshida K; Yokoi A; Kitagawa M; Sugiyama M; Yamamoto T; Nakayama J; Yoshida H; Kato T; Kajiyama H; Yamamoto Y
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 36929268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signatures of copy number alterations in human cancer.
    Steele CD; Abbasi A; Islam SMA; Bowes AL; Khandekar A; Haase K; Hames-Fathi S; Ajayi D; Verfaillie A; Dhami P; McLatchie A; Lechner M; Light N; Shlien A; Malkin D; Feber A; Proszek P; Lesluyes T; Mertens F; Flanagan AM; Tarabichi M; Van Loo P; Alexandrov LB; Pillay N
    Nature; 2022 Jun; 606(7916):984-991. PubMed ID: 35705804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic signatures differentiate uterine and soft tissue leiomyosarcoma.
    Hasan NM; Sharma A; Ruzgar NM; Deshpande H; Olino K; Khan S; Ahuja N
    Oncotarget; 2021 Aug; 12(16):1566-1579. PubMed ID: 34381562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational landscape of inflammatory breast cancer.
    Bertucci F; Lerebours F; Ceccarelli M; Guille A; Syed N; Finetti P; Adélaïde J; Van Laere S; Goncalves A; Viens P; Birnbaum D; Mamessier E; Callens C; Bedognetti D
    J Transl Med; 2024 Apr; 22(1):374. PubMed ID: 38637846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis.
    Boscolo Bielo L; Repetto M; Crimini E; Belli C; Setola E; Parma G; Fusco N; Barberis M; Guerini Rocco E; Marra A; Colombo N; Curigliano G
    Oncologist; 2024 May; ():. PubMed ID: 38716772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Landscape of driver gene events, biomarkers, and druggable targets identified by whole-genome sequencing of glioblastomas.
    van de Geer WS; Hoogstrate Y; Draaisma K; Robe PA; Bins S; Mathijssen RHJ; French P; van de Werken HJG; de Vos FYF
    Neurooncol Adv; 2022; 4(1):vdab177. PubMed ID: 35047820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-exome sequencing of calcitonin-producing pancreatic neuroendocrine neoplasms indicates a unique molecular signature.
    Döring C; Peer K; Bankov K; Bollmann C; Ramaswamy A; Di Fazio P; Wild PJ; Bartsch DK
    Front Oncol; 2023; 13():1160921. PubMed ID: 37771441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic potential of whole exome sequencing in the clinical management of metachronous colorectal cancer liver metastases.
    Heczko L; Hlaváč V; Holý P; Dvořák P; Liška V; Vyčítal O; Fiala O; Souček P
    Cancer Cell Int; 2023 Nov; 23(1):295. PubMed ID: 38008721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma.
    Marino-Enriquez A; Novotny JP; Gulhan DC; Klooster I; Tran AV; Kasbo M; Lundberg MZ; Ou WB; Tao DL; Pilco-Janeta DF; Mao VY; Zenke FT; Leeper BA; Gokhale PC; Cowley GS; Baker LH; Ballman KV; Root DE; Albers J; Park PJ; George S; Fletcher JA
    Clin Cancer Res; 2023 Dec; 29(24):5128-5139. PubMed ID: 37773632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted and shallow whole genome sequencing identifies therapeutic opportunities in p53abn endometrial cancers.
    Jamieson A; Sobral de Barros J; Cochrane DR; Douglas JM; Shankar S; Lynch BJ; Leung S; Martin S; Senz J; Lum A; Drew Y; Gilks CB; Huntsman DG; McAlpine JN
    Clin Cancer Res; 2024 Mar; ():. PubMed ID: 38536067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of somatic mutation landscapes in Chinese versus European breast cancer patients.
    Zhu B; Joo L; Zhang T; Koka H; Lee D; Shi J; Lee P; Wang D; Wang F; Chan WC; Law SH; Tsoi YK; Tse GM; Lai SW; Wu C; Yang S; Yang Chan EY; Shan Wong SY; Wang M; Song L; Jones K; Zhu B; Hutchinson A; Hicks B; Prokunina-Olsson L; Garcia-Closas M; Chanock S; Tse LA; Yang XR
    HGG Adv; 2022 Jan; 3(1):100076. PubMed ID: 35047861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.